Related Experiment Videos
[Experimental studies on hepatic cancer chemo-embolization]
Abstract:
Mitomycin microspheres (MMC MS), which contain about 5% of MMC and have an average diameter of 45 +/- 8 microns, were administered into the rat hepatic artery in a preclinical study on antitumor treatment for human hepatic cancer. Plasma GOT and GPT activities increased markedly 24 hours after MMC MS injection; they decreased to within the normal range within 3 days of the injection. Hepatic necrobiosis was observed in the area adjacent to the hepatic arterioles containing MMC MS, but was not observed in rats injected with placebo microspheres. The hepatic vein blood of MMC MS treated rats contained a markedly high level of MMC, compared to rats treated in the conventional fashion with MMC. Furthermore, MMC MS remained within hepatic arterioles for over 3 weeks.
Insights
Mitomycin microspheres (MMC MS) show potential for liver cancer treatment by concentrating the drug in hepatic arterioles. While causing temporary liver enzyme elevation, MMC MS provide sustained drug delivery with localized effects.
Area of Science:
- Oncology
- Pharmacology
- Biomedical Engineering
Context:
- Preclinical study investigating novel drug delivery systems for human hepatic cancer.
- Focus on intra-arterial administration of mitomycin microspheres (MMC MS).
- Evaluation of liver function and drug distribution in a rat model.
Purpose:
- To assess the efficacy and safety of mitomycin microspheres (MMC MS) for hepatic cancer treatment.
- To evaluate the pharmacokinetic profile and localized drug retention of MMC MS.
- To compare MMC MS delivery with conventional mitomycin C administration.
Summary:
- Mitomycin microspheres (5% MMC, 45±8 microns) were administered intra-arterially in rats.
- Transient increases in plasma GOT and GPT were observed, returning to normal within 3 days.
- Localized hepatic necrobiosis occurred near MMC MS-containing arterioles; sustained MMC levels were detected in hepatic veins.
Impact:
- Mitomycin microspheres demonstrate prolonged retention in hepatic arterioles (>3 weeks).
- This localized delivery system achieves higher hepatic mitomycin concentrations compared to conventional methods.
- Results suggest potential for enhanced antitumor efficacy and reduced systemic toxicity in liver cancer therapy.